On November 3, 2015 Merrimack (Nasdaq: MACK) reported that it will present research on several of its therapeutic candidates at the 2015 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), November 5-9, 2015 at Hynes Convention Center in Boston (Press release, Merrimack, NOV 3, 2015, View Source [SID:1234507928]). Presentations include recent preclinical data from Merrimack’s antibody engineering technology platforms.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data will be presented in three poster sessions:

Poster Sessions

Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors (Abstract #A89)
Poster Session A
Session Title: Immune Modulators
Friday, November 6, 2015, 12:15 PM – 3:15 PM ET
Exhibit Hall C-D

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations (Abstract #LB-B05)
Poster Session B
Session Title: EGFR/Her2
Saturday, November 7, 2015, 12:30 PM – 3:30 PM ET
Exhibit Hall C-D

Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands (Abstract #LB-C25)
Poster Session C
Session Title: Drug Resistance and Modifiers
Sunday, November 8, 2015, 12:30 PM – 3:30 PM ET
Exhibit Hall C-D